低分子肝素在不同VTE风险AECOPD患者血栓前抗凝治疗中的应用分析

Analysis of low molecular weight heparin in the treatment of AECOPD patients with different VTE risk

目的:探究Caprini血栓风险评估不同VTE风险的慢性阻塞性肺疾病急性加重期(AECOPD)患者辅助抗凝治疗的效果。方法:选取我院近年来收治的80例AECOPD患者,分为对照组和实验组各40例,对照组采用常规基础治疗,实验组在常规基础治疗同时根据VTE风险分级给予低分子肝素抗凝,对两组患者凝血指标进行比较。结果:实验组VTE风险分级越高的患者经低分子肝素辅助治疗后纤维蛋白原(Fbg)、D-二聚体和同型半胱氨酸(Hcy)指标好转越明显,不同分级间的差异具有统计学意义(P<0.05),而凝血功能指标和血气分析结果在不同VTE风险分级患者中差异无统计学意义(P>0.05)。结论:采用Caprini血栓风险评估模型对AECOPD患者进行VTE筛选,能更好地指导辅助抗凝治疗,值得临床推广。

Objective： To explore the effect of Caprini risk assessment model at assessing patients＇ VTE risk in the treatment of acute exacerbation of chronic obstructive pulmonary disease（ AECOPD）. Methods： Eighty cases of AECOPD patients treated in our hospital were divided into control group and experimental group. The control group received conventional treatment while the experimental group were given low molecular weight heparin in addition to conventional treatment. The coagulation parameters were compared between the two groups. Results： The patients in the experimental group with higher VTE risk improved more obviously in Fbg,two D-dimer and Hcy after treatment with statistically significant differences between the different grades（ P 〈0. 05）. There were no significant differences of coagulation parameters and blood gas analysis indexes in patients with different VTE risks in experimental group（ P 〉0. 05）. Conclusion： Caprini risk assessment model plays an important role in the selection of AECOPD patients with VTE risk.